Heparin does not appear to impact 1- and 2-year mortality in people with cancer, according to a Cochrane review of 18 trials involving nearly 9,600 individuals. Studies included patients mainly with small cell lung cancer, non-small cell lung cancer, and pancreatic cancer. Among the findings:
- The impact on blood thinners is uncertain, or small at best.
- Injectable blood thinners reduce the risk of blood clots by about half.
- They appear to increase the risk of major bleeding by 4 more per 1,000, and minor bleeding by 17 more per 1,000.
- Quality of life impact is not certain.
The decision to start heparin therapy should balance the benefits and downsides, and should include patient values/preferences, the reviewers noted.
Akl E, Kahale L, Hakoum M, et al. Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database of Systematic Reviews. 2017, Issue 9. Art. No.: CD006652. doi:10.1002/14651858.CD006652.pub5.
This Week's Must Reads
Durvalumab Post-Chemoradiotherapy in NSCLC Assessed, N Engl J Med; ePub 2017 Sep 8; Antonia, et al
Cochrane on Detecting CRC in Patients with IBD, Cochrane; 2017 Sep 18; Bye, Nguyen, Parker, et al
Lymph Node Removal During Endometrial Ca Surgery, Cochrane; 2017 Oct 2; Frost, Webster, et al
Cochrane on Reducing Neoplasia in Molar Pregnancy, Cochrane; 2017 Sep 11; Wang, Fu, Hu, et al
Cochrane on Reconstructing the Pancreatic Stump, Cochrane; 2017 Sep 12; Cheng, Briarava, et al
Must Reads in Clinical Guidelines
Cochrane on Heparin Impact in People with Cancer , Cochrane; 2017 Sep 11; Akl, Kahale, et al
Cochrane on EDMA for Bladder Cancer Treatment, Cochrane; 2017 Sep 12; Jung, Gudeloglu, et al
Cochrane on Oxycodone for Cancer-Related Pain, Cochrane; 2017 Aug 22; Schmidt-Hansen, et al
ASCO Updates Stage IV NSCLC Treatment Guideline, J Clin Oncol; ePub 2017 Aug 14; Hanna, et al
Guideline: Biomarkers to Guide BC Treatment, J Clin Oncol; ePub 2017 Jul 10; Krop, et al